期刊
GUT AND LIVER
卷 3, 期 2, 页码 101-107出版社
EDITORIAL OFFICE GUT & LIVER
DOI: 10.5009/gnl.2009.3.2.101
关键词
Probiotics; Irritable bowel syndrome; Bifidobacterium bifidum
资金
- Ministry of Health & Welfare, Republic of Korea [A060546-AD1101-06NI]
- Korea Health Promotion Institute [A040036] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Background/Aims: Irritable bowel syndrome (IBS) is a troublesome disease. Some strains of probiotics reportedly exert remarkable immunomodulatory effects, and so we designed a prospective double-blind randomized placebo-controlled clinical study to assess their effects in Korean adults with IBS. Methods: IBS patients who met Rome III criteria were randomly assigned to receive composite probiotics or placebo. A total of 20 billion Iyophilized bacteria were administered twice daily for 8 weeks. Primary outcome variables were symptom scores consisting of abdominal pain, flatulence, defecation discomfort, and sum of symptom scores. A visual analogue scale was used to quantify the severity. Secondary outcome variables consisted of the quality of life and bowel habits including defecation frequency and stool form. Results: Thirty-six and 34 patients were randomized to the probiotics and placebo groups, respectively. Intention-to-treat analysis showed significant reductions in pain after 8 weeks of treatment: -31.9 and -17.7 in the probiotics and placebo groups, respectively (p=0.045). The reductions in abdominal pain, defecation discomfort, and sum of scores were more significant in 58 patients with a score of at least 3 on the baseline stool-form scale. Conclusions: Composite probiotics containing Bifidobacterium bifidum BGN4, Lactobacillus acidophilus AD031, and other species are safe and effective, especially in patients who excrete normal or loose stools. (Gut and Liver 2009;3:101-107)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据